8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-10-05 AccNo: 0001193125-26-413177 Size: 192 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.